NO20052472L - 1-acyl-pyrrolidinderivater for behandling av virale infeksjoner. - Google Patents

1-acyl-pyrrolidinderivater for behandling av virale infeksjoner.

Info

Publication number
NO20052472L
NO20052472L NO20052472A NO20052472A NO20052472L NO 20052472 L NO20052472 L NO 20052472L NO 20052472 A NO20052472 A NO 20052472A NO 20052472 A NO20052472 A NO 20052472A NO 20052472 L NO20052472 L NO 20052472L
Authority
NO
Norway
Prior art keywords
alkyl
treatment
acyl
aryl
viral infections
Prior art date
Application number
NO20052472A
Other languages
English (en)
Inventor
Pritom Shah
Charles David Hartley
Peter Howes
Dav Haigh
Deborah Lynette Jackson
Martin John Slater
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224774A external-priority patent/GB0224774D0/en
Priority claimed from GB0229470A external-priority patent/GB0229470D0/en
Priority claimed from GB0317141A external-priority patent/GB0317141D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20052472L publication Critical patent/NO20052472L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Antivirale midler med formel (I) hvor: A representerer hydroksy; D representerer aryl eller heteroaryl; E representerer hydrogen, CI-6alkyl, aryl, heteroaryl eller heterocyklyl; G representerer hydrogen eller eventuelt substituert C,-6alkyl; J representerer C,-6alkyl, heterocyklylalkyl, arylalkyl eller heteroarylalkyl; og salter, solvater og estere derav; forutsatt at når A er forestret for å danne -OR hvor R er utvalgt fra rett- eller forgrenet alkyl, aralkyl, aryloksyalkyl eller aryl, da er R forskjellig fra tert-butyl; fremgangsmåte for deres fremstilling, fannasøytiske sammensetninger som innbefatter dem og fremgangsmåter for anvendelse av dem ved HCV-behandling er tilveiebragt.
NO20052472A 2002-10-24 2005-05-23 1-acyl-pyrrolidinderivater for behandling av virale infeksjoner. NO20052472L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0224774A GB0224774D0 (en) 2002-10-24 2002-10-24 Compounds
GB0229470A GB0229470D0 (en) 2002-12-18 2002-12-18 Compounds
GB0317141A GB0317141D0 (en) 2003-07-22 2003-07-22 Compounds
PCT/EP2003/011813 WO2004037818A1 (en) 2002-10-24 2003-10-22 1-acyl-pyrrolidine derivatives for the treatment of viral infections

Publications (1)

Publication Number Publication Date
NO20052472L true NO20052472L (no) 2005-05-23

Family

ID=32180212

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052472A NO20052472L (no) 2002-10-24 2005-05-23 1-acyl-pyrrolidinderivater for behandling av virale infeksjoner.

Country Status (18)

Country Link
US (1) US7304087B2 (no)
EP (1) EP1554274B1 (no)
JP (1) JP2006506455A (no)
KR (1) KR20050057670A (no)
AR (1) AR041816A1 (no)
AT (1) ATE418554T1 (no)
AU (1) AU2003276172A1 (no)
BR (1) BR0315417A (no)
CA (1) CA2503471A1 (no)
CO (1) CO5550450A2 (no)
DE (1) DE60325498D1 (no)
IS (1) IS7851A (no)
MA (1) MA27524A1 (no)
MX (1) MXPA05004435A (no)
NO (1) NO20052472L (no)
PL (1) PL376454A1 (no)
TW (1) TW200418848A (no)
WO (1) WO2004037818A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304494D0 (en) * 2003-02-27 2003-04-02 Glaxo Group Ltd Compounds
GB0408995D0 (en) * 2004-04-22 2004-05-26 Glaxo Group Ltd Compounds
GB0423672D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
GB0423673D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
US7115749B2 (en) 2004-10-29 2006-10-03 Schering Corporation Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents
GB0519486D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519485D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519478D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519488D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
BRPI0808089A2 (pt) 2007-02-28 2014-07-15 Conatus Pharmaceuticals Inc Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
CA2686051A1 (en) 2007-05-04 2008-11-13 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of hcv infection
US20090053175A1 (en) * 2007-08-24 2009-02-26 Yat Sun Or Substitute pyrrolidine derivatives
CN104710365A (zh) 2008-04-28 2015-06-17 旭化成制药株式会社 苯丙酸衍生物及其用途
CN102176911B (zh) 2008-08-11 2014-12-10 葛兰素史密丝克莱恩有限责任公司 新的腺嘌呤衍生物
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
MX2011001662A (es) 2008-08-11 2011-03-24 Glaxosmithkline Llc Derivados de purina para usarse en el tratamiento de enfermedades alergicas, inflamatorias e infecciosas.
AU2011214468B2 (en) 2010-02-10 2015-05-28 Glaxosmithkline Llc 6-amino-2-{ [ (1S)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8H-purin-8-one maleate
EP2534148A1 (en) 2010-02-10 2012-12-19 GlaxoSmithKline LLC Purine derivatives and their pharmaceutical uses
US9340530B2 (en) 2012-03-06 2016-05-17 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists
CA2938476A1 (en) 2014-02-20 2015-08-27 Glaxosmithkline Intellectual Property (No.2) Limited Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
RU2722019C2 (ru) 2015-12-03 2020-05-26 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
RU2018137389A (ru) 2016-04-07 2020-05-12 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Гетероциклические амиды, полезные в качестве модуляторов
IL295649A (en) 2016-04-07 2022-10-01 Glaxosmithkline Ip Dev Ltd Heterocyclic amides are useful as protein modulators
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
TW201927771A (zh) 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
CN114302875A (zh) 2019-05-16 2022-04-08 斯汀塞拉股份有限公司 氧代吖啶基乙酸衍生物及使用方法
CN114391015A (zh) 2019-05-16 2022-04-22 斯汀塞拉股份有限公司 苯并[b][1,8]萘啶乙酸衍生物和使用方法
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0821670A1 (en) 1995-04-21 1998-02-04 Novartis AG N-aroylamino acid amides as endothelin inhibitors
AU1804299A (en) 1997-12-08 1999-06-28 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
WO1999037204A1 (en) 1998-01-26 1999-07-29 Massachusetts Institute Of Technology Fluorescence imaging endoscope
PL343678A1 (en) * 1998-04-23 2001-08-27 Abbott Lab Pyrrolidines as inhibitors of neuraminidases
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EP1118287B1 (de) * 2000-01-21 2004-11-24 Alois Ing. Sampl Steckbares Regalsystem
US6713502B2 (en) 2000-05-05 2004-03-30 Smithkline Beecham Corporation Anti-infectives
EP1339708A2 (en) 2000-11-20 2003-09-03 Scios Inc. Indole-type inhibitors of p38 kinase
BR0213760A (pt) 2001-10-26 2004-10-19 Upjohn Co Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
US20050009873A1 (en) 2001-11-02 2005-01-13 Gianpaolo Bravi Acyl dihydro pyrrole derivatives as hcv inhibitors
EP1556258B1 (en) 2002-10-28 2006-05-10 Marquage Antivol Sherlock, Inc. Method of preventing theft of vehicles using intensive marking

Also Published As

Publication number Publication date
AR041816A1 (es) 2005-06-01
US7304087B2 (en) 2007-12-04
MXPA05004435A (es) 2005-07-26
EP1554274B1 (en) 2008-12-24
CA2503471A1 (en) 2004-05-06
US20060258720A1 (en) 2006-11-16
WO2004037818A1 (en) 2004-05-06
CO5550450A2 (es) 2005-08-31
KR20050057670A (ko) 2005-06-16
PL376454A1 (en) 2005-12-27
TW200418848A (en) 2004-10-01
ATE418554T1 (de) 2009-01-15
EP1554274A1 (en) 2005-07-20
DE60325498D1 (de) 2009-02-05
IS7851A (is) 2005-05-19
JP2006506455A (ja) 2006-02-23
AU2003276172A1 (en) 2004-05-13
BR0315417A (pt) 2005-08-16
MA27524A1 (fr) 2005-09-01

Similar Documents

Publication Publication Date Title
NO20052472L (no) 1-acyl-pyrrolidinderivater for behandling av virale infeksjoner.
NO20072547L (no) 4-metoksymetyl-pyrrolidin-2-karboksylsyreforbindelser og derivater derav som hepatitt C virusinhibitorer
TW200616994A (en) Novel thiophene derivatives
NO20061170L (no) Piperazinderivater for behandling av HIV-infeksjoner
NO20082934L (no) Antivirale nukleotider
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
NO20051527D0 (no) 3-(sulfonamidoetyl) -indol-derivater for anvendelse som glukocorticoid-mimetica ved behandling av inflammatoriske, allergiske og proliferative sykdommer.
EA201101492A1 (ru) Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
NO20085269L (no) 2-tioksantinderivater som fungerer som MPO-inhibitorer
NO20052580L (no) Blandinger for behandling av infeksjon av Flavivirida viruser
WO2006046030A3 (en) Tetracyclic indole derivatives as antiviral agents
WO2006027628A3 (en) Naphthalimide derivatives as antiviral agents
NO20051165L (no) Benzotiazolderivater som har -adrenoerseptorantagonist aktivitet
NO20062370L (no) Amidderivater
NO20055688L (no) Organiske forbindelser
NO20071274L (no) Inhibitorer av hepatitt C virus RNA-avhengig RNA polymerase, og sammensetninger og behandlinger ved anvendelse av samme.
WO2003084938A3 (en) Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
NO20053133L (no) Kjemiske forbindelser.
WO2002018324A3 (en) Immunoregulatory compounds, derivatives thereof and their use
WO2006113552A3 (en) Cyanoarylamines
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
NO20060963L (no) Nikotinamidderivater anvendelige som PDE4-inhibitorer
NO20062491L (no) Benzoksazinderivter og deres anvendelse
NO20075409L (no) Substituerte aminoalkyl- og amidoalkyl-benzopyranderivater
RS101204A (en) N-acylaminobenzene derivatives as selective monoamine oxidase b inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application